Company intelligence / Profile preview

Catalyst Development

Coral Gables, Florida, USAcatalystdg.com ↗

Ownership: Private
Development stage: Other

Overview

Catalyst has three commercial products: Firdapse for LEMS, Fycompa for certain types of epilepsy, and Agamree for DMD. Firdapse is FDA-approved for both adults and children with LEMS; Agamree was recently approved as a novel corticosteroid alternative for DMD; Fycompa is marketed for partial-onset seizures[1][2][3][4][5][6].

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small moleculeCorticosteroidAntiepileptic drug
Industry: Biotech

Partnerships

Strategic partnerships to expand global commercial footprint; specific partners not named publicly as of June 2025BioMarin (past licensing)Northwestern University (past licensing)

Beyond the preview

Go deeper on Catalyst Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Catalyst Development.

Explore the full profile